Advances in Oncopathology Research

ORIGINAL RESEARCH

Open Access

Clinical Application of Three-Dimensional Esophageal Computed Tomography Combined with Serum β -hCG in Diagnosis of Esophageal Cancer

Yimin Zhang 1,2,*, Wen Shen 1,3

- Radiology Department, Deqing County People's Hospital, Wukang Town, Deqing County, 313299 Huzhou, Zhejiang, China
- ^{2.} Wenzhou Medical University, 325035 Wenzhou, China
- 3. Southern Medical University, 510515 Guangzhou, China

DOI: https://doi.org/10.62767/aor101.5966

Keywords

Three-dimensional esophageal CT Serum β -hCG Esophagus cancer Diagnose

* Correspondence

Yimin Zhang

Radiology Department, Deqing County People's Hospital, Wukang Town, Deqing County, 313299 Huzhou, Zhejiang, China; Wenzhou Medical University, 325035

Wenzhou, China

E-mail: zymin_zy@163.com

Received: 3 July 2023
Revised: 23 August 2023
Accepted: 31 August 2023
Published: 11 September 2023

Advances in Oncopathology Research 2025; 1(1): 1-7.

Abstract

Background: This study is undertaken to explore the diagnostic value of three-dimensional esophageal computed tomography (CT) combined with human chorionic gonadotropin β subunit (β -hCG) in esophageal cancer. Methods: The clinical data of 76 patients with suspected esophageal cancer admitted to our hospital from August 2022 to February 2023 were retrospectively analyzed. According to the pathological diagnosis results of gastroscopic biopsy, 49 patients with esophageal cancer were assigned to the esophageal cancer group and 27 patients with benign cancer were assigned to the benign group. Three-dimensional esophageal CT and serum $\beta\,\text{-hCG}$ examination were performed in all patients. The results of serum β-hCG level detection and three-dimensional esophageal CT examination were collected and compared with the pathological diagnosis results of gastroscopy biopsy. The diagnostic value of three-dimensional esophageal CT combined with serum β -hCG was analyzed by receiver operating characteristic (ROC) curve area (AUC). Results: The serum β-hCG level in esophageal carcinoma group was significantly higher than that in benign group (ρ < 0.05). The accuracy of three-dimensional esophageal CT and serum β-hCG in the diagnosis of esophageal cancer was 92.11% and 81.58%, respectively. The AUC of three-dimensional esophageal CT, β -hCG, and their joint detection in the diagnosis of esophageal cancer was 0.922, 0.914, and 0.958, respectively. Conclusion: Three-dimensional esophageal CT combined with serum β-hCG may have a better diagnostic value in esophageal cancer.

1 Introduction

Esophageal cancer is a common and highly invasive gastrointestinal tumor, which is caused by pathological changes of esophageal epithelial mucosa cells, with difficulty in eating and dysphagia as the main manifestation, seriously affecting the quality of patients' life, with a high incidence and mortality [1-4]. Since the tumor of early esophageal cancer only invades the mucosa or submucosa instead of the deep layer, without the occurrence of lymph node metastasis and the early symptoms, it is often difficult for patients to detect. This disease can easily progress to the middle and late stages, which increases the difficulty of treatment, eventually leading to poor prognosis. Therefore, accurate diagnosis and intervention in the early stages of the disease are effective means of reducing the incidence and mortality of esophageal cancer, which is important for improving the clinical outcome of patients with esophageal cancer [5,6].

Gastroscopic biopsy is the current gold standard for the diagnosis of esophageal cancer, but it is more invasive to the patient, which leads to poor compliance [7,8]. Three-dimensional esophageal computed tomography (CT) is a common clinical cancer examination modality, which is non-invasive, painless, and easy to detect, with high accuracy, sensitivity, specificity, and good imaging effect. For some patients who cannot receive gastroscopy, three-dimensional esophageal CT is a more convenient alternative method [9].

Clinically, diverse biomarkers have been used for the diagnosis of esophageal cancer, including protein biomarkers, circulation blood and cancer stem cell surface markers [10]. Combining three-dimensional CT-radiomic features with diagnosis biomarkers such as N6-methyladenosine RNA is beneficial for developing diagnostic and therapeutic methods against esophageal cancer [11].

Human chorionic gonadotropin β subunit (β -hCG) is a common tumor marker, which is contributive to early diagnosis, clinical staging, and efficacy assessment of tumors [12]. It is highly expressed in metastatic cancers and contributes to disease invasiveness [13].

Increase in serum β -hCG can be found in gestational trophoblastic tumors as well as malignancies in other organs, and is associated with aggressive disease and poor prognosis [14]. Similarly, serum β -hCG also shows high diagnostic sensitivity in early diagnosis of esophageal cancer as patients with esophageal cancer tend to have high serum value of β -hCG, as compared with healthy control subjects [15]. Hence, evaluating the diagnostic value of β -hCG is of great significance to the condition, prognosis and life quality of patients with esophageal cancer. Based on this, this study aims to provide a reference for clinical esophageal cancer diagnosis by comparing the diagnostic value of different examination modalities for esophageal cancer.

2 Materials and methods

2.1 General data

Clinical data of 76 patients with suspected esophageal cancer admitted to our hospital from August 2022 to February 2023 were retrospectively analyzed. According to the pathological diagnosis results of gastroscopic biopsy, 49 patients with esophageal cancer were assigned to the esophageal cancer group and 27 patients with benign cancer were allocated to the benign group.

2.2 Inclusion and exclusion criteria

2.2.1 Inclusion criteria

(1) All patients underwent gastroscopic biopsy, three-dimensional esophageal CT, and serum β -hCG test. (2) Patients aged 18-45 years old.

2.2.2 Exclusion criteria

(1) Patients underwent hormone therapy or other drug therapy within the last 3 months before being admitted to our hospital. (2) Patients with hyperthecosis syndrome and pituitary prolactinoma. (3) Patients with endocrine disease. (4) Patients with coagulation disorders. (5) Patients with malignant tumors. (6) Patients with mental disorders and poor adherence to treatment. (7) Pregnant and lactating women.

2.3 Methods

2.3.1 Three-dimensional esophageal CT examination

GE Optima 64 row multi-slice spiral CT scanner (GE HealthCare, Little Chalfont, Buckinghamshire, UK) was used. The patient was instructed to fast for 6 hours before the examination. The examination parameters were set as voltage of 120 kV, current of 250 mA, slice thickness of 7 mm, slice spacing of 7 mm, scanning time of 10-15 s, enhanced arterial phase of 25-30 s, and venous phase of 55-60 s. Patients received an intramuscular injection of 654-2 (20 mg, Herbest, Baoji, China) 30 minutes before the examination, and orally administrated with 1500 mL diluted 20% mannitol (MedChemExpress, Monmouth Junction, NJ, USA) before the examination, with a ratio of 5:1. Patients took the supine position, and held their breath after deep breathing. Patients' lower necks, chests, and upper abdomens were scanned, and physician adjusted the parameters such as slice spacing and slice thickness in a timely manner to obtain a clear image.

2.3.2 Detection of serum β-hCG

5 mL of fasting peripheral venous blood was drawn from both groups of patients in the early morning, left to stand at room temperature for 30-60 min. The blood samples were centrifuged at 3000 r/min for 10 min, after which the serum was separated and stored

at -20 $^{\circ}$ C for measurement. Serum β -hCG level was determined using enzyme-linked immunosorbent kit purchased from Tianjin Biochip Technology Co., Ltd (Tianjin, China) (Jin Medical Device Registration Approval No. 20152400068).

2.4 Observational indicators

General data and serum β -hCG level were collected and compared. Three-dimensional esophageal CT and serum β -hCG in two groups were compared with pathological diagnostic results of gastroscopic biting biopsy.

2.5 Statistical methods

SPSS 20.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis, the counting data were represented by examples (%), and comparisons between the two groups were made using x^2 test. Measurement data were expressed as mean \pm standard deviation. Paired samples ℓ -test was used for the comparison at different time points in the same group. The diagnostic value of three-dimensional esophageal CT combined with serum β -hCG was analyzed using the area under the receiver operating characteristic (ROC) curve (AUC). The difference was considered statistically significant at ρ < 0.05.

3 Results

3.1 Comparision of general data in the two groups

There was no statistically significant difference in the comparison of gender and age between the two groups of patients ($\rho > 0.05$), as seen in Table 1.

3.2 Comparison of serum β -hCG level in the two groups

Serum β -hCG level in esophageal cancer group was higher than that in benign group (ρ < 0.05), as shown in Table 2.

Table 1 Comparison of general data in the two groups (mean \pm standard deviation).

		Gender (cases)		_	Typing (cases)			
Groups	Cases	Male	Female	Age (years old)	Esophageal squamous cell carcinoma	Poorly differentiated adenocarcinoma	Mucinous adenocarcinoma	Small cell carcinoma
Benign group	27	13	14	45.48 ± 8.28	-	-	-	-
Esophageal cancer group	49	25	24	46.45 ± 7.54	13	17	9	10
t/x ²		0	.057	0.518		-		
ρ		0	.811	0.606		-		

Table 2 Comparison of serum β -hCG level in the two groups (mean \pm standard deviation).

Groups	Cases	β-hCG (U/mL)
Benign group	27	24.16 ± 7.83
Esophageal cancer group	49	55.73 ± 22.41
t		7.068
P		<0.001

3.3 Comparison of three-dimensional esophageal CT and serum β -hCG with pathological diagnostic results of gastroscopic biting biopsy

The diagnosis of three-dimensional esophageal CT was positive in 47 cases and negative in 29 cases. The diagnosis of serum β -hCG was positive in 41 cases and negative in 35 cases, and pathological diagnosis of gastroscopic biting biopsy was positive in 49 cases and negative in 27 cases. The accuracy of three-dimensional esophageal CT and serum β -hCG in

the diagnosis of esophageal cancer was 92.11% and 81.58%, respectively. All results were listed in Table 3 and Table 4.

3.4 ROC curves of three-dimensional esophageal CT, serum β -hCG, and their joint detection

AUC of three-dimensional esophageal CT, serum β -hCG, and their joint detection in the diagnosis of esophageal cancer was 0.922, 0.914, and 0.958, respectively. The results were displayed in Table 5 and Figure 1.

Table 3 Comparison of three-dimensional esophageal CT with pathological diagnostic results of gastroscopic biting biopsy.

/ -		Gold standard			
		Positive (+)	Negative (-)	Total	
Three-dimensional	Positive (+)	45	2	47	
	Negative (-)	4	25	29	
esophageal CT	Total	49	27	76	
Accur	асу		92.11%		

Table 4 Comparison of serum β -hCG with pathological diagnostic results of gastroscopic biting biopsy.

/ -		Gold standard			
		Positive (+)	Negative (-)	Total	
	Positive (+)	38	3	41	
Serum β-hCG	Negative (-)	11	24	35	
	Total	49	27	76	
Accu	racy		81.58%		

Table 5 ROC curve analysis of three-dimensional esophageal CT, serum β-hCG, and their joint detection.

Indicators	AUC	Optimal cut-off value	Sensitivity	Specificity	p
Three-dimensional esophageal CT	0.922	0.500	0.918	0.926	<0.001
Serum β-hCG	0.914	32.570	0.776	0.889	< 0.001
Joint detection	0.958	0.600	0.918	0.926	< 0.001




Figure 1 ROC curves of three-dimensional esophageal CT, serum β -hCG, and their joint detection.

4 Discussion

Due to the complicated pathogenesis of esophageal cancer and unclear etiology, a single indicator cannot make a clear diagnosis of the disease, so multiple indicators need to be jointly used to improve its diagnostic level [16]. In order to improve the diagnosis of esophageal cancer, and ameliorate the efficacy and prognosis of patients, this paper explored the application value of three-dimensional esophageal CT combined with serum $\beta\text{-hCG}$ in esophageal cancer. Our results suggested that three-dimensional esophageal CT combined with $\beta\text{-hCG}$ may have a better application value in the diagnosis of esophageal cancer.

The accuracy and density resolution of CT imaging diagnosis are high, which can show the size, metastasis path, diffusion range, and surrounding infiltration of the esophageal mass, and have certain advantages in the diagnosis of esophageal cancer [17]. The outcomes of this study revealed that Exploration and Verfication Publishing

three-dimensional esophageal CT has a high accuracy rate in the diagnosis of esophageal cancer. Compared with two-dimensional imaging, three-dimensional esophageal CT can demonstrate the overall morphological changes of the esophagus by intuitively presenting stereoscopic three-dimensional images, clearly show the lymphatic metastasis of each region and the infiltration of surrounding tissues and provide a more accurate structure of the tumor, which is contributive to performing more accurate preoperative staging, as well as assessing and predicting the total area of the tumor to select optimal surgical treatment [18,19]. When performing diagnostic plan examination of esophageal cancer, the metastasis of esophageal cancer in lungs, chest wall and liver can also be observed due to the wide scanning area [19]. Therefore, three-dimensional esophageal CT has a better application value in the diagnosis of esophageal cancer.

β -hCG is a hormone produced by tumor

syncytiotrophoblast cells whose level in serum or urine will be increased in patients with some non-trophoblastic malignant tumor diseases such as testicular cancer, embryoma, and cervical carcinoma [12]. Accordingly, β -hCG is widely used in clinical practice for the diagnosis of cervical carcinoma and ovarian tumor [12,20]. This study found that serum β -hCG level in patients with esophageal cancer was higher than that in benign patients, indicating that β -hCG level is associated with the occurrence and development of the disease and can be used as a diagnostic basis for esophageal cancer. The possible reason for this is that serum β -hCG is a glycoprotein synthesized and secreted by tumor syncytiotrophoblast cells, and patients with esophageal cancer have weaker immune function and higher risk of infection as compared with normal people or benign patients due to the influences of tumors, which leads to rapid cell proliferation and production of a large number of β-hCG, resulting in the elevation of β -hCG level in the bodies [21]. Hence, serum β-hCG can be used as an auxiliary diagnostic indicator for esophageal cancer.

Moreover, gastroscopic biopsy, three-dimensional esophageal CT, and serum β -hCG examination were performed in all patients with suspected esophageal cancer, and the detection rates of different diagnostic methods were compared. The results uncovered that the diagnostic accuracy of three-dimensional esophageal CT combined with β -hCG examination was high. Three-dimensional esophageal CT could clearly show the morphology of the tumor in the esophagus and the involvement of tissues and organs, and lymphatic metastasis through the secondary analysis of the data, which has a certain value in the diagnosis of esophageal cancer [21]. When combined with β -hCG examination, it has high accuracy, sensitivity, and specificity, with an application value higher than a single diagnostic index, which can reduce the under-diagnosis rate of esophageal cancer

[21]. Therefore, three-dimensional esophageal CT combined with β -hCG examination has high diagnostic value for patients with esophageal cancer. However, in this study, due to the limited number of sample cases and review time, the results were not sufficient to represent all patients' conditions, and the diagnosis of three-dimensional esophageal CT combined with β -hCG examination needs further investigation to improve the relevant theoretical research.

In conclusion, three-dimensional esophageal CT combined with serum β -hCG may have a better diagnostic value in esophageal cancer.

Acknowledgements

Not applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

Author Contributions

Data curation, Formal analysis and Methodology, W.S.; Conceptualization, Writing - Original draft, Writing review and editing, Y.Z. All authors have read and agreed to the published version of the manuscript.

Ethics Approval and Consent to Participate

The study was approved by Medical Ethics Committee, and the patients were informed and consented.

Funding

This research received no external funding.

Availability of Data and Materials

The data presented in this study are available on request from the corresponding author.

Supplementary Materials

Not applicable.

References

- [1] Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. *Surgery Today* 2020; 50(1): 12-20.
- [2] Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. *Annals of Surgery* 2014; 260(2): 259-266.
- [3] Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. *Asian Journal of Surgery* 2018; 41(3): 210-215.
- [4] Elliott JA, Docherty NG, Eckhardt HG, et al. Weight Loss, Satiety, and the Postprandial Gut Hormone Response After Esophagectomy: A Prospective Study. *Annals of Surgery* 2017; 266(1): 82-90.
- [5] Visaggi P, Barberio B, Ghisa M, et al. Modern diagnosis of early esophageal cancer: from blood biomarkers to advanced endoscopy and artificial intelligence. *Cancers* 2021; 13(13): 3162.
- [6] Mönig S, Chevallay M, Niclauss N, et al. Early esophageal cancer: the significance of surgery, endoscopy, and chemoradiation. *Annals of the New York Academy of Sciences* 2018; 1434(1): 115-123.
- [7] Ishihara R, Goda K, Oyama T. Endoscopic diagnosis and treatment of esophageal adenocarcinoma: introduction of Japan Esophageal Society classification of Barrett's esophagus. *Journal of Gastroenterology* 2019; 54(1): 1-9.
- [8] Li D, Zhang L, Liu Y, et al. Specific DNA methylation markers in the diagnosis and prognosis of esophageal cancer. *Aging* 2019; 11(23): 11640-11658.
- [9] Li L, Wang S, Zheng J, et al. Clinical value of upper gastrointestinal radiography and three-dimensional esophageal CT in the diagnosis of esophageal cancer. *Journal of Medical Imaging* 2023; 33(4): 693-696.
- [10] Liu K, Zhao T, Wang J, et al. Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer. *Cancer Letters* 2019; 458: 21-28.
- [11] Brancato V, Garbino N, Mannelli L, et al. Impact of radiogenomics in esophageal cancer on clinical outcomes: A pilot study. *World Journal of Gastroenterology* 2021; 27(36): 6110.
- [12] Li H, Li C, Gong J. Diagnostic significance of serum alpha-fetoprotein combined with β -hCG level in

- nonseminomatous germ cell tumor. *Health Vocational Education* 2018; 36(17): 155-157.
- [13] Singh J, Swaminathan U, Sharada P, et al. Estimation of expression of beta-human chorionic gonadotropin levels through progression of disease from normal to epithelial dysplasia to malignancy. *Journal of Oral and Maxillofacial Pathology: JOMFP* 2019; 23(1): 108.
- [14] Kang S, Zaidi A J, Shokouh-Amiri M, et al. A case report of paraneoplastic syndrome in β -hCG-secreting duodenal adenocarcinoma. *Journal of Gastrointestinal Oncology* 2019; 10(6): 1151.
- [15] Bagaria B, Bagaria A, Singh M, et al. Diagnostic sensitivity of serum carcinoembryonic antigen, carbohydrate antigen 19–9, alpha-fetoprotein, and beta-human chorionic gonadotropin in esophageal carcinoma (receiver operating characteristic curve analysis). *Clinical Cancer Investigation Journal* 2015; 4(3): 312-317.
- [16] Zheng R, He S, Zhu H, et al. Diagnostic value of CYFRA21-1, CA19-9 and β -hCG in patients with esophageal cancer and its correlation with T lymphocyte subsets. *Journal of Modern Medical Laboratory* 2021; 36(1): 51-53+91.
- [17] Liang S. Barium contrast and CT diagnostic value of esophageal cancer. *Imaging Research and Medical Application* 2021; 5(10): 161-162.
- [18] Yue Y, Li N, Shahid H, et al. Gross Tumor Volume Definition and Comparative Assessment for Esophageal Squamous Cell Carcinoma From 3D 18F-FDG PET/CT by Deep Learning-Based Method. *Frontiers in Oncology* 2022; 12: 799207.
- [19] Geng Y, Ren Y, Li Z, et al. The value of CT iterative reconstruction in preoperative evaluation of hilar cholangiocarcinoma resection. *Progress in Modern Chinese General Surgery* 2022; 25(6): 467-469.
- [20] Dinis de Sousa M, Barata M, Miranda AR, et al. Beta-HCG secretion by a pulmonary pleomorphic carcinoma: A case report. *Respiratory Medicine Case Reports* 2021; 34: 101528.
- [21] Gao Y, Gong C, Wang H, et al. Clinical value of combined examination of serum β -HCG PCT and CRP and secretion GBS in predicting chorioamnionitis and neonatal infection in pregnant women with premature rupture of membranes. Hebei Medical Journal 2021; 27(6): 930-934.